

# 2023 Annual Meeting American Cancer Society National Lung Cancer Roundtable



December 4–5  
Washington, D.C.

Pathways of Care: Focusing on the Patient Experience  
Across the Lung Cancer Continuum



# Welcome

Welcome to the American Cancer Society National Lung Cancer Roundtable's (ACS NLCRT) 7th Annual Meeting!

We're pleased to welcome you to the Grand Hyatt in Washington, DC for two days of presentations and discussions, exchanging ideas with colleagues, and making new connections to advance the work of creating lung cancer survivors. We'll share the progress and activities of the ACS NLCRT task groups, volunteers and member organizations, and advances across the lung cancer community over the past year, and spark new collaborations and activities as we recognize how much more work there is still to do.

Formally launched by the American Cancer Society in 2017, the ACS NLCRT has galvanized 220 organizational members, and 212 leading experts, patients, and caregiver advocates at the national, state, and local levels to come together in support of our shared mission to create lung cancer survivors. Our work is comprehensive and covers the lung cancer continuum – from risk reduction, tobacco prevention and control, early detection (screening and incidental lung nodule management), and guideline-based staging, biomarker testing, and treatment to survivorship, including overarching issues such as stigma and nihilism and health equity, to tactical approaches including state coalition efforts and policy initiatives. We are glad to have you partnering with us.

Collectively, we work to improve patient and provider education, evidence generation, and partnerships among the clinical, research, public health, and advocacy communities, with the goal of ultimately transforming outcomes for individuals with lung cancer and their families. This year's theme, *Pathways of Care: Focusing on the Patient Experience Across the Lung Cancer Continuum*, is core to why we're here. Patients are integral to our annual meeting, actively participating in keynote, general, and concurrent sessions throughout the two days. While every individual's cancer journey is unique, when taken together, the stories reveal themes and perspectives that are not always apparent to those who are not facing them first-hand. Our hope is that this year's annual meeting will enhance our individual and collective understanding towards the patient-centered care we all strive to provide, founded on the needs and perspectives of those we serve.

This year's meeting will feature two keynote speakers. On day 1, Ms. Laurie Fenton Ambrose, CEO of GO2 for Lung Cancer, will share her experiences working in lung cancer policy, from her early days as a staffer on Capitol Hill to her current leadership of the nation's leading lung cancer advocacy organization. On day 2, Dr. Eliseo Pérez-Stable, the Director of the National Institute on Minority Health and Health Disparities (NIMHD) at the National Institutes of Health, will address research and clinical science gaps in diverse populations. Both keynote presentations will be followed by moderated panel discussions and questions from the audience.

We heard your feedback from last year about what you value in our gatherings and have brought back the popular smaller group sessions from prior meetings to create a more engaging and interactive environment in which all attendees can actively participate and share ideas, thoughts, and questions. Each day there will be an extended 90-minute set of six smaller concurrent breakout sessions highlighting topic-specific panels covering the lung cancer continuum, addressing hot topics and incorporating voices from patients and the patient advocate community.

You also told us that there was a strong desire for more breathing room in our content-packed agendas to exchange ideas and connect with colleagues, so we've added more discussion time and longer breaks between sessions. We've also re-engineered our reception layout to be welcoming and facilitate socializing and engagement, as well as including posters throughout the space on Monday night that showcase the work of 30 of our ACS NLCRT members and volunteers. We hope you'll enjoy the format, and your conversations continue into the evening and day 2!

We are grateful to our partners who make our annual meeting and critical work together possible. AbbVie, The American College of Radiology, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Foundation Medicine, Genentech, Gilead, Guardant Health, Johnson & Johnson, Merck, Novartis, Novocure, Regeneron, Roche, Sanofi, and Takeda all share the passion and conviction that we can best make a difference in the lives of individuals affected by lung cancer when we come together, bringing our unique strengths and perspectives to find solutions to complex problems.

We are here at our 7th Annual Meeting with a shared sense of urgency and the belief that we make the greatest impact on the lives of patients with lung cancer when we understand their experiences across the lung cancer continuum, and address challenges with patient perspectives in mind. It is that belief that embodies the mission of the Roundtable.

Thank you for being an important part of our efforts this week and into the future as we work to create lung cancer survivors and thrivers!

With gratitude,



*Ella A. Kazerooni, MD, MS  
ACS NLCRT Chair  
University of Michigan*



*Douglas E. Wood, MD  
ACS NLCRT Vice Chair  
University of Washington*



*Robert A. Smith, PhD  
ACS NLCRT ACS Chair  
American Cancer Society*



*Lauren S. Rosenthal, MPH  
ACS NLCRT Strategic Director  
American Cancer Society*

# Agenda

Day 1: Monday, December 4, 2023		
7:00–8:00am	<b>Breakfast &amp; Registration</b>	Independence Lobby
8:00–8:30am	<b>General Session 1</b> <i>Welcome, Overview &amp; Patient Advocate Story</i>  <b>Speakers</b> <b>Ella A. Kazerooni, MD, MS, FACR, FACC, FSABI</b> Chair, ACS National Lung Cancer Roundtable Professor, University of Michigan <b>Welcome &amp; Overview of ACS NLCRT</b>  <b>Robert A. Smith, PhD, FSBI</b> ACS Chair, ACS National Lung Cancer Roundtable SVP, Cancer Screening, American Cancer Society <b>American Cancer Society Lung Cancer Screening Guideline</b>  <b>John Stewart</b> <b>Patient Advocate Story</b>	Independence Ballroom
8:30–10:00am	<b>General Session 2</b> <i>Lung Cancer Policy Keynote &amp; Panel Discussion</i>  <b>Keynote</b> <b>Laurie Fenton Ambrose</b> Chief Executive Office GO2 for Lung Cancer  <b>Moderator</b> <b>Gregory Kane, MD, MACP</b> Chair, Department of Medicine Thomas Jefferson University  <b>Panelists</b> <b>A. Mark Fendrick, MD</b> University of Michigan <b>Affordable Care Act</b>  <b>Timothy Merchant</b> RadNet <b>Recent Policy Wins</b>  <b>Ella A. Kazerooni, MD, MS, FACR, FACC, FSABI</b> Chair, ACS NLCRT <b>NCQA HEDIS Measure Update</b>  <b>Marissa Brown</b> ACS Cancer Action Network <b>ACS CAN Policy Perspective</b>  <b>Ruth Carlos, MD, MS, FACR</b> University of Michigan <b>Screening as an Episode of Care</b>	Independence Ballroom

10:00–10:20am	<b>Networking Break</b>									
10:20–11:50am	<p><b>General Session 3</b>  <i>Patient Advocate Panel: Learning from Patients' Lived Experiences</i></p> <p><b>Co-Moderators</b></p> <table border="0"> <tr> <td><b>Jill Feldman</b> Co-Founder EGFR Resisters</td> <td><b>Laura Petrillo, MD</b> Dept. of Medicine, Palliative Care Massachusetts General Hospital</td> </tr> </table> <p><b>Panelists</b></p> <table border="0"> <tr> <td><b>Donnita Butler</b> Patient Advocate</td> <td><b>Ameish Govindarajan, MD</b> Department of Medicine MSKCC</td> </tr> <tr> <td><b>Montessa Lee</b> Patient Advocate</td> <td><b>Aurora Lucas</b> Patient Advocate</td> </tr> <tr> <td><b>Daniel West</b> Patient Advocate</td> <td></td> </tr> </table>	<b>Jill Feldman</b> Co-Founder EGFR Resisters	<b>Laura Petrillo, MD</b> Dept. of Medicine, Palliative Care Massachusetts General Hospital	<b>Donnita Butler</b> Patient Advocate	<b>Ameish Govindarajan, MD</b> Department of Medicine MSKCC	<b>Montessa Lee</b> Patient Advocate	<b>Aurora Lucas</b> Patient Advocate	<b>Daniel West</b> Patient Advocate		
<b>Jill Feldman</b> Co-Founder EGFR Resisters	<b>Laura Petrillo, MD</b> Dept. of Medicine, Palliative Care Massachusetts General Hospital									
<b>Donnita Butler</b> Patient Advocate	<b>Ameish Govindarajan, MD</b> Department of Medicine MSKCC									
<b>Montessa Lee</b> Patient Advocate	<b>Aurora Lucas</b> Patient Advocate									
<b>Daniel West</b> Patient Advocate										
11:50am–12:50pm	<b>Networking Lunch</b>	Independence Ballroom								
12:50pm–1:00pm	<b>Travel to Concurrent Session Rooms</b>									
1:00–2:30pm	<b>Series 1: Concurrent Sessions A–F</b>									
	<p><b>Concurrent Session A: Population vs Individual Risk Assessment for Lung Cancer Screening Eligibility</b></p> <p><b>Moderator</b>  <b>Robert A. Smith, PhD, FSBI</b>          American Cancer Society</p> <p><b>Panelists</b></p> <table border="0"> <tr> <td><b>Richard Hoffman, MD, MPH</b> Cancer Epidemiology Population Science Program University of Iowa</td> <td><b>Jill Feldman</b> Co-Founder EGFR Resisters</td> </tr> <tr> <td><b>Hormuzd Katki, PhD</b> Division of Cancer Epidemiology &amp; Genetics National Cancer Institute</td> <td><b>Lecia Sequist, MD, MPH</b> Director, Cancer Early Detection and Diagnostics Clinic Massachusetts General Hospital</td> </tr> </table>	<b>Richard Hoffman, MD, MPH</b> Cancer Epidemiology Population Science Program University of Iowa	<b>Jill Feldman</b> Co-Founder EGFR Resisters	<b>Hormuzd Katki, PhD</b> Division of Cancer Epidemiology & Genetics National Cancer Institute	<b>Lecia Sequist, MD, MPH</b> Director, Cancer Early Detection and Diagnostics Clinic Massachusetts General Hospital	Lafayette Park				
<b>Richard Hoffman, MD, MPH</b> Cancer Epidemiology Population Science Program University of Iowa	<b>Jill Feldman</b> Co-Founder EGFR Resisters									
<b>Hormuzd Katki, PhD</b> Division of Cancer Epidemiology & Genetics National Cancer Institute	<b>Lecia Sequist, MD, MPH</b> Director, Cancer Early Detection and Diagnostics Clinic Massachusetts General Hospital									

	<p><b>Concurrent Session B: What do Patients Need and Want to Know Before Lung Cancer Surgery and/or Radiation Treatment?</b></p> <p><b>Moderator</b>  <b>Douglas E. Wood, MD, FACS, FRCSEd</b>  Vice Chair, ACS National Lung Cancer Roundtable  Professor, University of Washington</p> <p><b>Panelists</b></p> <table border="0"> <tr> <td><b>Terri Ann DiJulio</b> Patient Advocate</td> <td><b>Thomas K. Varghese, Jr. MD, MS, MBA, FACS, MAMSE</b> Department of Surgery University of Utah</td> </tr> <tr> <td><b>Drew Moghanaki, MD, MPH</b> Dept. of Radiation Oncology UCLA</td> <td></td> </tr> </table>	<b>Terri Ann DiJulio</b> Patient Advocate	<b>Thomas K. Varghese, Jr. MD, MS, MBA, FACS, MAMSE</b> Department of Surgery University of Utah	<b>Drew Moghanaki, MD, MPH</b> Dept. of Radiation Oncology UCLA		Tiber B		
<b>Terri Ann DiJulio</b> Patient Advocate	<b>Thomas K. Varghese, Jr. MD, MS, MBA, FACS, MAMSE</b> Department of Surgery University of Utah							
<b>Drew Moghanaki, MD, MPH</b> Dept. of Radiation Oncology UCLA								
	<p><b>Concurrent Session C: Optimizing the Use of Lung Cancer Biomarkers in Practice</b></p> <p><b>Moderator</b>  <b>Gerard A. Silvestri, MD, MS, Master FCCP</b>  Department of Medicine  Medical University of South Carolina</p> <p><b>Panelists</b></p> <table border="0"> <tr> <td><b>Cori Chandler, MPA</b> State &amp; Local Campaigns ACS Cancer Action Network</td> <td><b>Terri Conneran</b> Patient Advocate KRAS Kickers</td> </tr> <tr> <td><b>Adam H. Fox, MD</b> Department of Medicine Medical University of South Carolina</td> <td><b>Bruce E. Johnson, MD, FASCO</b> Department of Medicine Dana-Farber Cancer Institute</td> </tr> <tr> <td><b>Christine M. Lovly, MD, PhD</b> Department of Medicine Vanderbilt-Ingram Cancer Center</td> <td><b>Ignacio I. Wistuba, MD</b> Dept. of Translational Molecular Pathology MD Anderson Cancer Center</td> </tr> </table>	<b>Cori Chandler, MPA</b> State & Local Campaigns ACS Cancer Action Network	<b>Terri Conneran</b> Patient Advocate KRAS Kickers	<b>Adam H. Fox, MD</b> Department of Medicine Medical University of South Carolina	<b>Bruce E. Johnson, MD, FASCO</b> Department of Medicine Dana-Farber Cancer Institute	<b>Christine M. Lovly, MD, PhD</b> Department of Medicine Vanderbilt-Ingram Cancer Center	<b>Ignacio I. Wistuba, MD</b> Dept. of Translational Molecular Pathology MD Anderson Cancer Center	Banneker
<b>Cori Chandler, MPA</b> State & Local Campaigns ACS Cancer Action Network	<b>Terri Conneran</b> Patient Advocate KRAS Kickers							
<b>Adam H. Fox, MD</b> Department of Medicine Medical University of South Carolina	<b>Bruce E. Johnson, MD, FASCO</b> Department of Medicine Dana-Farber Cancer Institute							
<b>Christine M. Lovly, MD, PhD</b> Department of Medicine Vanderbilt-Ingram Cancer Center	<b>Ignacio I. Wistuba, MD</b> Dept. of Translational Molecular Pathology MD Anderson Cancer Center							
	<p><b>Concurrent D: Turning Away from Lung Cancer Stigma and Nihilism to Improve Care and Outcomes: New Data &amp; Perspectives</b></p> <p><b>Co-Moderators</b>  <b>Lisa Carter-Bawa, PhD, APRN, ANP-C, FAAN</b>  Director, Cancer Prevention Precision Control Institute  Hackensack Meridian Health</p> <p><b>Jamie L. Studts, PhD</b>  Department of Medicine  University of Colorado</p>	Farragut Square						



	<p><b>Panelists</b></p> <p><b>Smita Banerjee, PhD</b> Dept. of Behavioral Science MSKCC</p> <p><b>Dannell Boatman, EdD, MS</b> Research Associate WVU Cancer Institute</p> <p><b>Dusty Donaldson</b> Founder Dusty Joy Foundation</p> <p><b>Anne Stangl, PhD</b> Sr. Advisor, Div Global HIV/TB CDC</p>	
	<p><b>Concurrent Session E: Patients as Advocates and Partners in Research</b></p> <p><b>Moderator</b></p> <p><b>Michelle Mollica, PhD, MPH, RN, OCN</b> Deputy Director, Office of Cancer Survivorship National Cancer Institute</p> <p><b>Panelists</b></p> <p><b>Kristen Kimball</b> Patient Advocate White Ribbon Project</p> <p><b>Manali Patel, MD, MPH, MS, FASCO</b> Associate Professor of Medicine Stanford University</p> <p><b>Upal Basu Roy, PhD, MS, MPH</b> Vice President of Research LUNGeivity Foundation</p> <p><b>James Pantelas</b> Patient Advocate Department of Veterans Health</p>	<p>Tiber A</p>
	<p><b>Concurrent Session F: Promoting State-Based Initiatives and Partnerships</b></p> <p><b>Moderator</b></p> <p><b>Jessica Olson, PhD, MPH</b> Asst. Professor, Div. of Community Health Medical University of Wisconsin</p> <p><b>Panelists</b></p> <p><b>Pierre De Delva, MD, FACS</b> Chair, Interdisc. Thoracic Cancer Care University of Mississippi Medical Center</p> <p><b>Nikki Hayes, MPH</b> Branch Chief Comp. Cancer Control Branch CDC</p> <p><b>Lisa Mei, MPH</b> Consultant, Cancer Prevention &amp; Control Michigan Department of HHS</p> <p><b>Ronald Myers, PhD, DSW</b> Dept of Medical Oncology Thomas Jefferson University</p> <p><b>Jennifer Redmond Knight, DrPH</b> Dept. of Health Management and Policy UK Markey Cancer Center</p>	<p>Franklin-McPherson</p>
<p>2:30–2:45pm</p>	<p><b>Networking Break &amp; Travel to General Session Room</b></p>	

2:45–3:45pm	<p><b>General Session 4</b> <i>Updates on Select ACS NLCRT Initiatives</i></p> <p><b>Moderator</b> <b>Ella A. Kazerooni, MD, MS</b> Chair, ACS NLCRT University of Michigan</p> <p><b>Panelists</b> <b>Carey C. Thomson, MD, MPH, FCCP</b> Chair, Department of Medicine Mount Auburn Hospital/Beth Israel Lahey Health Associate Professor, Harvard Medical School <b><i>Accelerating Uptake and Implementation of Early Detection</i></b></p> <p><b>Debra S. Dyer, MD, FACP</b> Chair, Department of Radiology National Jewish Health <b><i>Best Practice Guide for Building an Early Detection Program</i></b></p> <p><b>Jamie L. Studts, PhD</b> Department of Medicine University of Colorado <b><i>Supporting Initiatives to Eliminate Lung Cancer Stigma &amp; Nihilism</i></b></p> <p><b>Farhood Farjah, MD, MPH, FACS</b> Department of Surgery University of Washington <b><i>Improving Guideline-Concordant Staging</i></b></p> <p><b>Jeffrey B. Velotta, MD, FACS</b> Division of Thoracic Surgery Kaiser Permanente Oakland <b><i>Lung Cancer Staging Education Tool</i></b></p> <p><b>Keith Singer</b> Founder and Executive Director Catch It In Time</p>	Independence Ballroom
3:50–4:50pm	<p><b>General Session 5</b> <i>Updates on Select ACS NLCRT Member Organization Initiatives</i></p> <p><b>Moderator</b> <b>Pierre De Delva, MD, FACS</b> Chairman, Interdisciplinary Thoracic Cancer Care University of Mississippi Medical Center</p> <p><b>Panelists</b> <b>Jane Kim, MD, MPH</b> Chief Consultant for Prev. Medicine US Dept. of Veterans Affairs</p> <p><b>Christopher Slatore, MD, MS</b> Associate Professor of Medicine Oregon Health &amp; Science University Portland VA Medical Center</p> <p><b><i>National Lung Cancer Screening Day Partnership</i></b></p> <p><b>Priyanka Senthil</b> Executive Director</p> <p><b>Shreya Papneja</b> National Director</p> <p><b>Mitchell Anderson</b> Intercollegiate Director</p> <p><b><i>American Lung Cancer Screening Initiative</i></b></p>	Independence Ballroom



	<p><b>Robert J. Volk, PhD</b>                  Department of Health Services Research                  MD Anderson Cancer Center  <i>American Academy of Family Physicians Partnership</i></p> <p><b>Adam H. Fox, MD</b>                  Pulmonologist                  Medical University of South Carolina  <i>Addressing Lung Cancer Biomarker Testing Through Project ECHO</i></p> <p><b>Linda Fleisher, PhD, MPH</b>                  Department of Health Communications &amp; Health Disparities                  Fox Chase Cancer Center  <i>ACS National Navigation Roundtable</i></p>	
4:50–5:00pm	<p><b>Closing of Day 1</b>  <b>Ella A. Kazerooni, MD, MS, FACR, FACC, FSAB</b>                  Chair, ACS National Lung Cancer Roundtable</p>	Independence Ballroom
5:15–6:45pm	<p><b>Network &amp; Poster Reception</b></p>	Independence B

## Day 2: Tuesday, December 5, 2023

7:00–8:00am	<p><b>Breakfast &amp; Registration</b></p>	Independence Lobby
8:00–8:30am	<p><b>General Session 6</b>  <i>Welcome, Recap of Day 1 &amp; Patient Advocate Story</i></p> <p><b>Speakers</b>  <b>Douglas Wood, MD, FACS, FRCSEd</b>                  Vice Chair, ACS National Lung Cancer Roundtable                  Professor, University of Washington  <i>Welcome &amp; Recap</i></p> <p><b>Daniel Cadigan, MD</b>  <i>Patient Advocate Story</i></p>	Independence Ballroom
8:30–8:45am	<p><b>Travel to Concurrent Session Rooms</b></p>	
8:45–10:15am	<p><b>Series 2: Concurrent Sessions G–L</b></p>	
	<p><b>Concurrent Session G: Critical Role of Oncology Navigation in Patient Care Across the Lung Cancer Continuum</b></p> <p><b>Moderator</b>  <b>Joelle T. Fathi, DNP, RN, ARNP, CTTS, FAAN</b>                  Chief Healthcare Delivery Officer                  GO2 for Lung Cancer</p>	Lafayette Park

	<p><b>Panelists</b></p> <p><b>Jennifer Aversano, MSN, RN, OCN, ONN-CG</b> Nurse Navigator Northwest Community Healthcare</p> <p><b>Meg Fay, BSN, RN</b> Nurse Manager, Excellence in Healthcare Delivery GO2 for Lung Cancer</p> <p><b>Neel Chudgar, MD</b> Dept. of Thoracic Surgery Montefiore Medical Center</p> <p><b>Claudia Miller, BSN, RN, OCN, ONN-CG</b> Thoracic Oncology Nurse Navigator Medical University of South Carolina</p>	
	<p><b>Concurrent Session H: Lung Cancer Screening for All Who are Eligible: An Implementation Science Approach</b></p> <p><b>Co-Moderators</b></p> <p><b>Raymond Osarogiagbon, MBBS, FACP</b> Chief Scientist Baptist Memorial Healthcare</p> <p><b>Jamie Studts, PhD</b> Department of Medicine University of Colorado</p> <p><b>Panelists</b></p> <p><b>David Chambers, DPhil</b> Dep. Dir., Implementation Science Office of the Director Division of Cancer Control and Population Sciences National Cancer Institute</p> <p><b>Mayuko Ito Fukunaga, MD, FCCP</b> Department of Medicine UMass Memorial Health</p> <p><b>Erin Hirsch, PhD</b> Department of Medical Oncology University of Colorado</p> <p><b>Elyse Park, PhD, MPH</b> Program Dir., Smokefree Support Massachusetts General Hospital</p>	<p>Independence FG</p>
	<p><b>Concurrent Session I: Advances in Tobacco Treatment in the Context of Lung Cancer Care</b></p> <p><b>Moderator</b></p> <p><b>Jamie Ostroff, PhD</b> Director, Tobacco Treatment Program Memorial Sloan Kettering Cancer Center</p> <p><b>Panelists</b></p> <p><b>Stephanie Land, PhD</b> Behavioral Research Program National Cancer Institute</p> <p><b>James Pantelas</b> Patient Advocate Department of Veterans Health</p> <p><b>Kathryn Taylor, PhD</b> Professor, Dept. of Oncology Georgetown University</p> <p><b>J. Lee Westmaas, PhD</b> Population Science Research American Cancer Society</p> <p><b>Graham Warren, MD, PhD, FASCO</b> Professor, Dept. of Radiation Oncology Medical University of South Carolina</p>	<p>Franklin- McPherson</p>


	<p><b>Concurrent Session J: The Evolving Landscape of Multimodality Therapy for Early-Stage Lung Cancer</b></p> <p><b>Moderator</b>  <b>Betty C. Tong, MD, MHS, MS</b>                  Department of Surgery                  Duke University</p> <p><b>Panelists</b></p> <table border="0"> <tr> <td><b>Estelamari Rodriguez, MD, MPH</b> Assoc. Director, Community Outreach Sylvester Comprehensive Cancer Center</td> <td><b>Jeffrey Velotta, MD, FACS</b> Division of Thoracic Surgery Kaiser Permanente Oakland</td> </tr> <tr> <td><b>Jing S. Zeng, MD</b> Department of Radiation Oncology University of Washington</td> <td><b>Daniel West</b> Patient Advocate</td> </tr> </table>	<b>Estelamari Rodriguez, MD, MPH</b> Assoc. Director, Community Outreach Sylvester Comprehensive Cancer Center	<b>Jeffrey Velotta, MD, FACS</b> Division of Thoracic Surgery Kaiser Permanente Oakland	<b>Jing S. Zeng, MD</b> Department of Radiation Oncology University of Washington	<b>Daniel West</b> Patient Advocate	<p>Independence I</p>		
<b>Estelamari Rodriguez, MD, MPH</b> Assoc. Director, Community Outreach Sylvester Comprehensive Cancer Center	<b>Jeffrey Velotta, MD, FACS</b> Division of Thoracic Surgery Kaiser Permanente Oakland							
<b>Jing S. Zeng, MD</b> Department of Radiation Oncology University of Washington	<b>Daniel West</b> Patient Advocate							
	<p><b>Concurrent Session K: Is Less More? Minimally Invasive Surgery vs Stereotactic Body Radiation Therapy</b></p> <p><b>Moderator</b>  <b>Gerard A. Silvestri, MD, MS, Master FCCP</b>                  Department of Medicine                  Medical University of South Carolina</p> <p><b>Panelists</b></p> <table border="0"> <tr> <td><b>Ian Bostock, MD, MS</b> Department of Surgery Medical University of South Carolina</td> <td><b>Farhood Farjah, MD, MPH, FACS</b> Department of Surgery University of Washington</td> </tr> <tr> <td><b>Upal Basu Roy, PhD, MS, MPH</b> Vice President of Research LUNGeity Foundation</td> <td><b>Anurag Singh, MD, FASTRO</b> Director of Radiation Research Roswell Park Cancer Center</td> </tr> </table>	<b>Ian Bostock, MD, MS</b> Department of Surgery Medical University of South Carolina	<b>Farhood Farjah, MD, MPH, FACS</b> Department of Surgery University of Washington	<b>Upal Basu Roy, PhD, MS, MPH</b> Vice President of Research LUNGeity Foundation	<b>Anurag Singh, MD, FASTRO</b> Director of Radiation Research Roswell Park Cancer Center	<p>Farragut Square</p>		
<b>Ian Bostock, MD, MS</b> Department of Surgery Medical University of South Carolina	<b>Farhood Farjah, MD, MPH, FACS</b> Department of Surgery University of Washington							
<b>Upal Basu Roy, PhD, MS, MPH</b> Vice President of Research LUNGeity Foundation	<b>Anurag Singh, MD, FASTRO</b> Director of Radiation Research Roswell Park Cancer Center							
	<p><b>Concurrent Session L: Lung Cancer Survivorship</b></p> <p><b>Co-Moderators</b></p> <table border="0"> <tr> <td><b>Jill Feldman</b> Co-Founder EGFR Resisters</td> <td><b>Laura Petrillo, MD</b> Dept. of Medicine, Palliative Care Massachusetts General Hospital</td> </tr> </table> <p><b>Panelists</b></p> <table border="0"> <tr> <td><b>Julia Agne, MD</b> Dept. of Medicine – Palliative Care James Comprehensive Cancer Center</td> <td><b>Mindy Hsu, MD</b> Dept. of Hematology/Oncology UH Cleveland Medical Center</td> </tr> <tr> <td><b>Matthew Schabath, PhD</b> Dept of Cancer Epidemiology &amp; Thoracic Oncology Moffitt Cancer Center</td> <td></td> </tr> </table>	<b>Jill Feldman</b> Co-Founder EGFR Resisters	<b>Laura Petrillo, MD</b> Dept. of Medicine, Palliative Care Massachusetts General Hospital	<b>Julia Agne, MD</b> Dept. of Medicine – Palliative Care James Comprehensive Cancer Center	<b>Mindy Hsu, MD</b> Dept. of Hematology/Oncology UH Cleveland Medical Center	<b>Matthew Schabath, PhD</b> Dept of Cancer Epidemiology & Thoracic Oncology Moffitt Cancer Center		<p>Independence H</p>
<b>Jill Feldman</b> Co-Founder EGFR Resisters	<b>Laura Petrillo, MD</b> Dept. of Medicine, Palliative Care Massachusetts General Hospital							
<b>Julia Agne, MD</b> Dept. of Medicine – Palliative Care James Comprehensive Cancer Center	<b>Mindy Hsu, MD</b> Dept. of Hematology/Oncology UH Cleveland Medical Center							
<b>Matthew Schabath, PhD</b> Dept of Cancer Epidemiology & Thoracic Oncology Moffitt Cancer Center								
<p>10:15–10:30am</p>	<p><b>Networking Break</b></p>	<p>Independence Lobby</p>						

10:30am-12:00pm	<p><b>General Session 7</b> <i>Health Equity and Lung Cancer Keynote &amp; Panel Discussion</i></p> <p><b>Co-Moderators</b>  <b>M. Patricia Rivera, MD, ATSF, FCCP</b>            Department of Medicine            University of Rochester</p> <p><b>Lori Sakoda, PhD</b>            Dept of Health Systems Science            Kaiser Permanente of Northern CA</p> <p><b>Keynote</b>  <b>Eliseo J. Pérez-Stable, MD</b>            Director, National Institute on Minority Health &amp; Health Disparities            National Institutes of Health</p> <p><b>Panelists</b>  <b>Morhaf Al Achkar, MD, PhD, MSCR, FAAFP</b>            Assoc. Center Director for Education            Karmanos Cancer Institute</p> <p><b>Leah Backhus, MD, MPH, FACS</b>            Assoc. Prof, Cardiothoracic Surgery            Stanford University</p> <p><b>Efrén Flores, MD</b>            Assoc. Prof, Department of Radiology            Harvard Medical School</p> <p><b>Scout, MA, PhD</b>            Executive Director            National LGBT Cancer Network</p>	Independence Ballroom
12:00-1:00pm	<p><b>Networking Lunch</b></p>	Independence Ballroom
1:00-2:00pm	<p><b>General Session 8</b> <i>PRO/PRO Debate: Regionalization of Lung Cancer Screening (Centralized vs Decentralized)</i></p> <p><b>Moderator</b>  <b>Douglas E. Wood, MD, FACS, FRCSEd</b>            University of Washington            Vice Chair, ACS NLCRT</p> <p><b>Panelists</b>  <b>Jane Kim, MD, MPH</b>            Chief Consultant for Prev. Medicine            US Department of Veterans Affairs</p> <p><b>Peter J. Mazzone, MD, MPH, FCCP</b>            Director, Lung Cancer Program            Cleveland Clinic</p> <p><b>Richard Wender, MD</b>            Chair, Family Medicine and Community Health            Penn Medicine</p>	Independence Ballroom
2:00-2:15pm	<p><b>General Session 9</b> <i>Close Out: Final Thoughts on 7th ACS NLCRT Annual Meeting</i></p> <p><b>Ella A. Kazerooni, MD, MS, FACR, FACC, FSABI</b>            Chair, ACS National Lung Cancer Roundtable</p>	Independence Ballroom

# Grand Hyatt Floorplan

## Declaration Level


Concurrent Sessions: Day 1	Room
Optimizing the Use of Biomarkers in Practice	Banneker
Patients as Advocates and Partners in Research	Tiber A
What Do Patients Want and Need to Know	Tiber B



## Independence Level

Concurrent Sessions: Day 1	Room
Population vs Individual Risk Assessment for LCS Eligibility	Lafayette Park
Promoting State-Based Initiatives and Partnerships	Franklin/Douglas
Turning Away from Lung Cancer Stigma and Nihilism	Farragut Square

Concurrent Sessions: Day 2	Room
Advances in Tobacco Treatment	Franklin/McPherson
Critical Role of Oncology Navigation	Lafayette Park
Is Less More? Surgery vs SBRT	Farragut Square
Lung Cancer Screening for All Who are Eligible	Independence F-G
Lung Cancer Survivorship	Independence H
The Evolving Landscape of Multimodality Therapy	Independence I



# Speaker and Moderator Biosketches

Biographical information about our speakers and session moderators can be found on the ACS National Lung Cancer Roundtable website ([www.NLCRT.org](http://www.NLCRT.org)), which can also be accessed through the QR code below.





# About The American Cancer Society National Lung Cancer Roundtable

## American Cancer Society Roundtable Overview

The American Cancer Society (ACS) is the leading cancer-fighting organization with a vision of ending cancer as we know it for everyone. It is the only organization working to improve the lives of people with cancer and their families through advocacy, research, and patient support. This provides ACS with unmatched reach – able to function as a leader and convener at the national and state levels to influence public policy, engage key leaders in advancing science and evidence-based patient care, and to serve as a trusted partner, communicator, and connector in our communities and with individual patients and their families. ACS seeks to ensure that everyone has an opportunity to prevent, detect, treat, and survive cancer.

The ACS has invested in the roundtable model since 1987, when the ACS and partners established the National Colorectal Cancer Roundtable (NCCRT). The NCCRT's *80% by 2018* campaign became one of the most effective and transformative public health cancer prevention campaigns, with over 1800 organizations making the pledge to become involved in reaching the goal of 80% screened for colorectal cancer by 2018. The follow-up campaign, *80% in Every Community*, continues the initiative, with a focus on health equity and ensuring that all communities meet this goal.

The success of the ACS NCCRT laid the foundation for the establishment of the ACS National Lung Cancer Roundtable (ACS NLCRT), the ACS National Navigation Roundtable (ACS NNRT), and the ACS National HPV Vaccination Roundtable (ACS NHVRT). Each were logical extensions of prior ACS work. Before 2017, with regard to lung cancer, the ACS was instrumental in efforts to evaluate low-dose CT (LDCT) for lung cancer screening, released one of the earliest lung cancer screening guidelines, and strongly advocated for Medicare coverage for lung cancer screening.

In the 2022 *President's Cancer Panel Report: Closing Gaps in Cancer Screening*, (<https://prescancer-panel.cancer.gov/report/cancerscreening/Recommendations.html>), the Panel endorsed ACS roundtables. Recommendation 1.2 specifically challenged the nation to, "Expand and strengthen National Cancer Roundtables that include a focus on cancer screening," adding that, in calling for new roundtables, the Panel's Report also appealed for increased support for two existing ACS roundtables, the ACS NCCRT and ACS NLCRT, "to allow important work on colorectal and lung cancer screening to continue and expand their reach to communities with low rates of screening and follow-up care."

---

***"The Panel believes that the National Roundtable model provides an ideal framework for bringing stakeholders together and addressing gaps in cancer screening and follow-up care, including inequities experienced by various sociodemographic groups."***

***- 2022 President's Cancer Panel***

---

The ACS has accepted the President's Cancer Panel's challenge, understanding that it has unique experience and capacity to build and expand roundtables, and lead critical initiatives. By the end of 2022, the ACS had launched two new roundtables – the National Breast Cancer Roundtable (ACS NBCRT) and the National Roundtable on Cervical Cancer (ACS NRTCC).

The goal of all ACS roundtables is the accelerated development of collaborative initiatives that would neither be feasible nor likely for any member organization to pursue alone. The ACS recognizes that many challenges warrant a comprehensive solution and a mission-oriented approach, one that must be met at both the national and local levels, and ACS roundtables offer a proven and effective platform to achieving these national goals more rapidly.

### ACS National Lung Cancer Roundtable's Work


The ACS has a strong history of improving the lives of individuals affected by lung cancer. Through research, it is currently funding 73 extramural grants that address lung cancer, totaling \$30 million. Since the 1990s, it has invested over \$29 million in research specific to lung cancer not related to tobacco – including research that found the link between the enzyme ALK and cancer, the key discovery that enabled industry researchers to develop crizotinib. The ACS was instrumental in international and U.S. efforts to evaluate LDCT for lung cancer screening and was one of the earliest organizations to release lung cancer screening guidelines. It strongly advocated for Medicare coverage for lung cancer screening when it appeared the Centers for Medicare & Medicaid Services (CMS) would not add LDCT screening to the benefits package based on concerns regarding quality. In fact, in a multi-organizational appeal to CMS, the ACS pledged to launch a new national roundtable focused on promoting best practices in lung cancer screening.

Since 2017, the ACS NLCRT has galvanized more than 220 public, private, and government member organizations and 212 leading experts, as well as patient and caregiver advocate representatives, to collectively address and problem-solve the challenges around lung cancer. While originally envisioned as having a focus on lung cancer screening, the early recommendations of its Steering Committee led the ACS NLCRT to broaden its scope to include the entire lung cancer continuum and to include industry partners in its mission. Through a multidimensional and multisectoral approach, the ACS NLCRT engages these experts and organizations in all areas to catalyze action to conceive, build, and strengthen innovative solutions.

After seven years of dedicated work, the ACS NLCRT has reached a point of maturity where ongoing research and design has produced valuable tools, publications, and initiatives. Our wide-ranging membership allows us to harness the collective power and expertise of the entire lung cancer community by connecting leaders, communities, and systems to improve equity and access. These relationships, both national and local, provide immediate partnerships and dissemination outlets for these tools and resources.

The ACS NLCRT's scope of work is comprehensive and covers the lung cancer continuum – from risk reduction, tobacco prevention and control, early detection (screening and incidental lung nodule management), and guideline-based staging, biomarker testing, and treatment to survivorship,

including overarching issues such as stigma and nihilism and health equity, to tactical approaches including state coalition efforts and policy initiatives. These themes fall under 3 strategic priorities and 1 cross-cutting priority. These priorities allow us to advance lung cancer-related best practices and health equity by identifying and working to overcome barriers to quality care and equitable access to care. The lists included here catalog select projects and initiatives that comprise the three priorities. More information about the ACS NLCRT and its current work can be found at [www.NLCRT.org](http://www.NLCRT.org) and in greater detail as part of the conference agenda.





- National Lung Cancer Screening Day
- LungPLAN® Return on Investment Modeling Tool
- State-Based Initiatives Planning Tool
- Professional Education Tools: Decision Aids for Primary Care Providers
- Lung Cancer Screening HEDIS Measure
- Best Practice Guide for Building a Lung Cancer Early Detection Program
- Lung Cancer Screening Messaging Guidebook
- Pleural Space | Conversations in Lung Cancer Podcast and Webinar Series
- Workshops to Accelerate Uptake of Lung Cancer Screening:
  - 2023 IT/EHR Workshop
  - 2024 Provider/Public Engagement and Outreach Workshop



- 2023 Lung Cancer Staging Summit
- 2025 Biomarker Summit
- Addressing Lung Cancer Biomarker Testing Through Project ECHO
  - 2023-2024: 7 states
  - 2024-2025: 7 states TBD
- Comprehensive Biomarker Testing Consensus Statement
- Acquiring Tissue for Lung Cancer Diagnosis and Comprehensive Biomarker Testing
- Process Map and Assessment Tool to Reduce Biomarker Testing Turnaround Time
- Survey of Thoracic Surgeons for Treating Stage IIIA Disease
- SEER-Medicare Analyses:
  - Outcomes of Surgery in Octogenarians
  - Rate of Biomarker Testing
  - Characteristics Associated with Testing and No Treatment



- 2023 Stigma Summit
- Lung Cancer Stigma – Communications Assessment Tool
- Empathic Communications Skills Training
- Commentary on Lung Cancer Nihilism
- Lung Cancer Stigma Educational Slide Deck

### Support and Strengthen State and Local Initiatives

*Individual states or regions know their population, and therefore are best positioned to tailor broad guidelines and best practices to fit the cultures and needs of the communities represented in their area.*

# Participant Roster

## Lynn Abbott-McCloud

LiveLung  
[lynn@livelung.org](mailto:lynn@livelung.org)

## Devon Adams

ACS Cancer Action Network  
[devon.adams@cancer.org](mailto:devon.adams@cancer.org)

## Adedayo Adeniyi

GO2 for Lung Cancer  
[aadeniyi@go2.org](mailto:aadeniyi@go2.org)

## Ahmed Agha

ALCSI  
[ahmed.gha@gwu.edu](mailto:ahmed.gha@gwu.edu)

## Julia Agne

The Ohio State University James  
Cancer Hospital  
[Julia.Agne@osumc.edu](mailto:Julia.Agne@osumc.edu)

## Morhaf Al Achkar

Karmanos Cancer Center  
[alachkarm@karmanos.org](mailto:alachkarm@karmanos.org)

## Melinda Aldrich

Vanderbilt University Medical  
Center  
[melinda.aldrich@vumc.org](mailto:melinda.aldrich@vumc.org)

## Sonja Alexander

Foundation Medicine, Inc.  
[salexander@foundationmedicine.com](mailto:salexander@foundationmedicine.com)

## Nikita Amanna

University of Virginia  
[vvr7bc@virginia.edu](mailto:vvr7bc@virginia.edu)

## Mitchell Anderson

American Lung Cancer Screening  
Initiative  
[mitchellbanderson@gmail.com](mailto:mitchellbanderson@gmail.com)

## Douglas Arenberg

University of Michigan  
[darenber@umich.edu](mailto:darenber@umich.edu)

## Nicki Augustyn

CHEST  
[naugustyn@chestnet.org](mailto:naugustyn@chestnet.org)

## Jennifer Aversano

Northwest Community Hospital  
[Javersano@nch.org](mailto:Javersano@nch.org)

## Peter Bach

Delfi Diagnostics  
[bach@delfidiagnostics.com](mailto:bach@delfidiagnostics.com)

## Leah Backhus

Stanford Medicine  
[lbackhus@stanford.edu](mailto:lbackhus@stanford.edu)

## Smita Banerjee

Memorial Sloan Kettering Cancer  
Center  
[BanerjeS@mskcc.org](mailto:BanerjeS@mskcc.org)

## Jim Baranski

Lung Cancer Foundation of America  
[jbaranski@lcfamerica.org](mailto:jbaranski@lcfamerica.org)

## Julie Barta

Thomas Jefferson University  
[julie.barta@jefferson.edu](mailto:julie.barta@jefferson.edu)

## Upal Basu Roy

LUNgevity Foundation  
[ubasuroy@lungevity.org](mailto:ubasuroy@lungevity.org)

## Kim Bathurst

RadNet  
[kimberly.bathurst@radnet.com](mailto:kimberly.bathurst@radnet.com)

## Alberta Becenti

Indian Health Service  
[alberta.becenti@ihs.gov](mailto:alberta.becenti@ihs.gov)

## Vickie Beckler

AstraZeneca  
[vickie.beckler@astrazeneca.com](mailto:vickie.beckler@astrazeneca.com)

## Chris Berg

[drchrisberg@outlook.com](mailto:drchrisberg@outlook.com)

## Dave Bjork

Research Evangelist Podcast  
[dave@davebjork.com](mailto:dave@davebjork.com)

## Alicia Blakey

American College of Radiology  
[ablakey@acr.org](mailto:ablakey@acr.org)

## Matthew Blum

UCHealth Memorial Hospital  
[matthew.blum@uchealth.org](mailto:matthew.blum@uchealth.org)

## Dannell Boatman

West Virginia University  
[dboatman@hsc.wvu.edu](mailto:dboatman@hsc.wvu.edu)

## Emily Bobyock

[ebobyock@aicaf.org](mailto:ebobyock@aicaf.org)

## Ian Bostock

Medical University of South  
Carolina  
[bostockr@musc.edu](mailto:bostockr@musc.edu)

## Mary Boulanger

Massachusetts General Brigham /  
Dana-Farber Cancer Institute  
[Mary\\_Boulanger@dfci.harvard.edu](mailto:Mary_Boulanger@dfci.harvard.edu)

## Phil Bowman

Catch It In Time  
[phil@studioarcadia.io](mailto:phil@studioarcadia.io)

## Carla Brathwaite

American College of Radiology  
[cbrathwaite@acr.org](mailto:cbrathwaite@acr.org)

## Deb Brown

American Lung Association  
[deb.brown@lung.org](mailto:deb.brown@lung.org)

## Marissa Brown

ACS Cancer Action Network  
[marissa.brown@cancer.org](mailto:marissa.brown@cancer.org)

## Deborah Buckles

Indiana University Simon  
Comprehensive Cancer Center  
[Dhudson@iupui.edu](mailto:Dhudson@iupui.edu)

## Sydney Burchell

GO2 for Lung Cancer  
[sburchell@go2.org](mailto:sburchell@go2.org)

**Judy Burleson**

American College of Radiology  
[jburleson@acr.org](mailto:jburleson@acr.org)

**Hannah Burson**

ACS NLCRT  
[hannah.burson@cancer.org](mailto:hannah.burson@cancer.org)

**Donnita Butler**

[donnitamae@yahoo.com](mailto:donnitamae@yahoo.com)

**Dan Cadigan**

[cadigand@proton.me](mailto:cadigand@proton.me)

**Beverlee Carlisle**

American College of Radiology  
[bcarlisle@acr.org](mailto:bcarlisle@acr.org)

**Ruth Carlos**

University of Michigan  
[rcarlos@med.umich.edu](mailto:rcarlos@med.umich.edu)

**Lisa Carter-Bawa**

Hackensack Meridian Health  
[lisa.carterbawa@hmh-cdi.org](mailto:lisa.carterbawa@hmh-cdi.org)

**Francisco Cartujano**

University of Rochester  
[francisco\\_cartujano@urmc.rochester.edu](mailto:francisco_cartujano@urmc.rochester.edu)

**Robert Caruano**

Regeneron Pharmaceuticals, Inc.  
[robert.caruano@regeneron.com](mailto:robert.caruano@regeneron.com)

**Patrick Casebolt**

American Cancer Society  
[patrick.casebolt@cancer.org](mailto:patrick.casebolt@cancer.org)

**Kate Caufield**

American Cancer Society  
[Kate.caufield@cancer.org](mailto:Kate.caufield@cancer.org)

**DuyKhanh (Mimi) Ceppa**

Indiana University School of Medicine  
[dpceppa@iupui.edu](mailto:dpceppa@iupui.edu)

**Shonta Chambers**

Patient Advocate Foundation  
[shonta.chambers@patientadvocate.org](mailto:shonta.chambers@patientadvocate.org)

**Cori Chandler**

ACS CAN  
[cori.chandler@cancer.org](mailto:cori.chandler@cancer.org)

**Kyle Chapman**

West Virginia University  
[kchapma4@hsc.wvu.edu](mailto:kchapma4@hsc.wvu.edu)

**Mythreyi Chatfield**

American College of Radiology  
[mchatfield@acr.org](mailto:mchatfield@acr.org)

**Maiyan Chau**

AstraZeneca  
[maiyan.chau@astrazeneca.com](mailto:maiyan.chau@astrazeneca.com)

**Mason Chiang**

BMS Foundation  
[mason.chiang@bms.com](mailto:mason.chiang@bms.com)

**Neel Chudgar**

Montefiore Medical Center  
[nchudgar@montefiore.org](mailto:nchudgar@montefiore.org)

**Meghan Clarke**

American Cancer Society  
[meghan.clarke@cancer.org](mailto:meghan.clarke@cancer.org)

**Jason Coleman**

American Cancer Society  
[JASON.COLEMAN@CANCER.ORG](mailto:JASON.COLEMAN@CANCER.ORG)

**Nancy Collar**

Inova Health System  
[nancy.collar@inova.org](mailto:nancy.collar@inova.org)

**Chris Conneran**

KRAS Kickers  
[chris@kraskickers.org](mailto:chris@kraskickers.org)

**Terri Conneran**

KRAS Kickers  
[terri@kraskickers.org](mailto:terri@kraskickers.org)

**Deena Cook**

[Rogerdeena@comcast.net](mailto:Rogerdeena@comcast.net)

**Lindsey Cotton**

Delfi Diagnostics  
[dr.lindseycotton@yahoo.com](mailto:dr.lindseycotton@yahoo.com)

**Angela Criswell**

GO2 for Lung Cancer  
[acriswell@go2.org](mailto:acriswell@go2.org)

**Hilary Crittenden**

Duke Health Lung Cancer Screening  
[hilary.crittenden@duke.edu](mailto:hilary.crittenden@duke.edu)

**Lisa Cruz**

Takeda Oncology  
[LISA.CRUZ@TAKEDA.COM](mailto:LISA.CRUZ@TAKEDA.COM)

**Elizabeth David**

University of Colorado  
[elizabeth.david@cuanschutz.edu](mailto:elizabeth.david@cuanschutz.edu)

**Pierre De Delva**

Univ. of Mississippi Medical Ctr.  
[pdedelva@umc.edu](mailto:pdedelva@umc.edu)

**Jessica Deering**

Cancer Action Coalition of Virginia  
[cacv@cancercoalitionofvirginia.org](mailto:cacv@cancercoalitionofvirginia.org)

**Karin Denes-Collar**

Masonic Cancer Alliance  
[kdenescollar@kumc.edu](mailto:kdenescollar@kumc.edu)

**Beth Dickson-Gavney**

American Cancer Society  
[beth.dickson-gavney@cancer.org](mailto:beth.dickson-gavney@cancer.org)

**Terri Ann DiJulio**

[Terri.Ann.DiJulio@gmail.com](mailto:Terri.Ann.DiJulio@gmail.com)

**Nicole Dixon**

Johnson & Johnson  
[ndixon1@its.jnj.com](mailto:ndixon1@its.jnj.com)

**Dusty Donaldson**

Lung Cancer Action Network  
[dusty@dustyjoy.org](mailto:dusty@dustyjoy.org)

**Paul Doria-Rose**

National Cancer Institute  
[doriarop@mail.nih.gov](mailto:doriarop@mail.nih.gov)

**Meriam Driss**

LUNgevity Foundation  
[mdriss@lungevity.org](mailto:mdriss@lungevity.org)

**Debra Dyer**

National Jewish Health  
[DebraDyer1@comcast.net](mailto:DebraDyer1@comcast.net)

**Jan Eberth**

Drexel University  
[jme336@drexel.edu](mailto:jme336@drexel.edu)

**Amy Ellis**

American Cancer Society  
[amy.ellis@cancer.org](mailto:amy.ellis@cancer.org)



**Mary Elmer**

Merck  
[mary\\_elmer@merck.com](mailto:mary_elmer@merck.com)

**Ana Espitia**

RadNet  
[ana.espitia@radnet.com](mailto:ana.espitia@radnet.com)

**Farhood Farjah**

University of Washington  
[ffarjah@uw.edu](mailto:ffarjah@uw.edu)

**Joelle Fathi**

GO2 for Lung Cancer  
[jfathi@go2.org](mailto:jfathi@go2.org)

**Meg Fay**

Go2 for Lung Cancer  
[mfay@go2.org](mailto:mfay@go2.org)

**Jill Feldman**

EGFR Resisters  
[jjfeldman4@sbcglobal.net](mailto:jjfeldman4@sbcglobal.net)

**A. Mark Fendrick**

University of Michigan  
[amfen@med.umich.edu](mailto:amfen@med.umich.edu)

**Laurie Fenton Ambrose**

GO2 for Lung Cancer  
[lfambrose@go2.org](mailto:lfambrose@go2.org)

**Scott Ferguson**

University of Wisconsin Carbone  
 Cancer Center  
[jsferguson@medicine.wisc.edu](mailto:jsferguson@medicine.wisc.edu)

**Andrea Ferris**

LUNgevity Foundation  
[aferris@lungevity.org](mailto:aferris@lungevity.org)

**Cathy Ferrone**

Gilead  
[catherine.ferrone@gilead.com](mailto:catherine.ferrone@gilead.com)

**Linda Fleisher**

Fox Chase Cancer Center  
[Linda.Fleisher@fcc.edu](mailto:Linda.Fleisher@fcc.edu)

**Efrén Flores**

Massachusetts General Hospital  
[eflores@mgh.harvard.edu](mailto:eflores@mgh.harvard.edu)

**Adam Fox**

Medical University of South  
 Carolina  
[fox.adamh@gmail.com](mailto:fox.adamh@gmail.com)

**Neal Freedman**

Tobacco Control Research  
 Branch, NCI  
[freedmanne@mail.nih.gov](mailto:freedmanne@mail.nih.gov)

**Audrey Frone**

Tanana Chiefs Conference  
[audrey.frone@tananachiefs.org](mailto:audrey.frone@tananachiefs.org)

**Michael Gieske**

St Elizabeth HealthCare  
[michael.gieske@stelizabeth.com](mailto:michael.gieske@stelizabeth.com)

**Kathleen Goss**

American Cancer Society  
[kathleen.goss@cancer.org](mailto:kathleen.goss@cancer.org)

**Ameish Govindarajan**

Memorial Sloan Kettering Cancer  
 Center  
[govinda@mskcc.org](mailto:govinda@mskcc.org)

**Joshua Gralapp**

Mercy BioAnalytics  
[josh.gralapp@mercybio.com](mailto:josh.gralapp@mercybio.com)

**Hannah Green**

American Lung Association  
[hannah.green@lung.org](mailto:hannah.green@lung.org)

**Grant Greenberg**

Lehigh Valley Health Network  
[grant.greenberg@lvhn.org](mailto:grant.greenberg@lvhn.org)

**Hildy Grossman**

Upstage Lung Cancer.org  
[Hildy@UpstageLungCancer.org](mailto:Hildy@UpstageLungCancer.org)

**Kristen Hackbarth**

Nevada Cancer Coalition  
[kristen@nevadacancercoalition.org](mailto:kristen@nevadacancercoalition.org)

**Blerta Hamza**

Washington Hospital Center  
[blerta.hamza@medstar.net](mailto:blerta.hamza@medstar.net)

**Paul Han**

NCI  
[paul.han@nih.gov](mailto:paul.han@nih.gov)

**Ethan Hardy**

ALCSI  
[ethanhardy76@gmail.com](mailto:ethanhardy76@gmail.com)

**Travis Harper**

Catch it in Time  
[travis@catchitintime.org](mailto:travis@catchitintime.org)

**Eric Hart**

Northwestern University  
[ehart@nm.org](mailto:ehart@nm.org)

**J. Rob Headrick**

CHI Memorial  
[rob@drheadrick.net](mailto:rob@drheadrick.net)

**Louise Henderson**

University of North Carolina at  
 Chapel Hill  
[louise\\_henderson@med.unc.edu](mailto:louise_henderson@med.unc.edu)

**Talia Henkle**

American Cancer Society  
[talia.henkle@cancer.org](mailto:talia.henkle@cancer.org)

**Jane Henley**

CDC  
[skh3@cdc.gov](mailto:skh3@cdc.gov)

**Erin Hirsch**

Hackensack Meridian Health  
[Erin.Hirsch@hmh-cdi.org](mailto:Erin.Hirsch@hmh-cdi.org)

**Lauren Hixenbaugh**

West Virginia University  
[lmccaule@hsc.wvu.edu](mailto:lmccaule@hsc.wvu.edu)

**Richard Hoffman**

University of Iowa  
[richard-m-hoffman@uiowa.edu](mailto:richard-m-hoffman@uiowa.edu)

**Korey Hofmann**

ACS NLCRT  
[korey.hofmann@cancer.org](mailto:korey.hofmann@cancer.org)

**Cosmina Hoge**

Gilead  
[Cosmina.Hogea@gilead.com](mailto:Cosmina.Hogea@gilead.com)

**Elizabeth Holtsclaw**

American Cancer Society  
[Elizabeth.Holtsclaw@cancer.org](mailto:Elizabeth.Holtsclaw@cancer.org)

**Jonathan Hontzas**

The University of Mississippi  
Medical Center  
[jhontzas@umc.edu](mailto:jhontzas@umc.edu)

**Craig Hooker**

Bristol Myers Squibb  
[craig.hooker@bms.com](mailto:craig.hooker@bms.com)

**Tom Houston**

AAFP  
[tphdoc@aol.com](mailto:tphdoc@aol.com)

**Melinda Hsu**

University Hospitals Seidman  
Cancer Center  
[melinda.hsu@uhhospitals.org](mailto:melinda.hsu@uhhospitals.org)

**Paige Humble**

Lung Cancer Initiative NC  
[phumble@lungcancerinitiativenc.org](mailto:phumble@lungcancerinitiativenc.org)

**Neville Irani**

HQUIP  
[Neville@hquip.org](mailto:Neville@hquip.org)

**Mayuko Ito Fukunaga**

University of Massachusetts  
[mayuko.itofukunaga@umassmed.edu](mailto:mayuko.itofukunaga@umassmed.edu)

**Ahmedin Jamal**

American Cancer Society  
[ahmedin.jamal@cancer.org](mailto:ahmedin.jamal@cancer.org)

**Bruce Johnson**

DFCI  
[bruce\\_johnson@dfci.harvard.edu](mailto:bruce_johnson@dfci.harvard.edu)

**Mike Johnson**

American College of Radiology  
[mjohnson@acr.org](mailto:mjohnson@acr.org)

**Nikki Johnston**

American Cancer Society  
[nikole.johnston@cancer.org](mailto:nikole.johnston@cancer.org)

**John Kang**

University of Washington Medical  
Center  
[jkang3@uw.edu](mailto:jkang3@uw.edu)

**Hasmeena Kathuria**

Boston University  
[hasmeena@bu.edu](mailto:hasmeena@bu.edu)

**Hormuzd Katki**

National Cancer Institute  
[katkih@mail.nih.gov](mailto:katkih@mail.nih.gov)

**Ella Kazerooni**

University of Michigan  
[ellakaz@umich.edu](mailto:ellakaz@umich.edu)

**Lauren Kearney**

Boston University  
[lekearn@bu.edu](mailto:lekearn@bu.edu)

**Kaitlyn Keen**

American Cancer Society  
[kaitlyn.keen@cancer.org](mailto:kaitlyn.keen@cancer.org)

**Jane Kim**

Department of Veterans Affairs  
[jane.kim3@va.gov](mailto:jane.kim3@va.gov)

**Kristen Kimball**

[kristen.kimball@gmail.com](mailto:kristen.kimball@gmail.com)

**Rachael King**

American Cancer Society  
[Rachael.King@cancer.org](mailto:Rachael.King@cancer.org)

**Rigwey King**

American Cancer Society  
[rigwey.king@cancer.org](mailto:rigwey.king@cancer.org)

**Kim Kinner**

American Cancer Society  
[kim.kinner@cancer.org](mailto:kim.kinner@cancer.org)

**Jennifer Redmond Knight**

University of Kentucky  
[jennifer.knight@uky.edu](mailto:jennifer.knight@uky.edu)

**Risha Kohli**

AbbVie  
[risha.kohli@abbvie.com](mailto:risha.kohli@abbvie.com)

**Sangkavi Kuhan**

ALSCI  
[skuhan@mgh.harvard.edu](mailto:skuhan@mgh.harvard.edu)

**Stephanie Land**

National Cancer Institute  
[landsr@nih.gov](mailto:landsr@nih.gov)

**Rebecca Landy**

National Cancer Institute  
[rebecca.landy@nih.gov](mailto:rebecca.landy@nih.gov)

**David LeDuc**

AstraZeneca  
[david.leduc@astrazeneca.com](mailto:david.leduc@astrazeneca.com)

**Liam Lee**

AstraZeneca  
[liam.lee@astrazeneca.com](mailto:liam.lee@astrazeneca.com)

**Montessa Lee**

LCFA  
[montessa1978@gmail.com](mailto:montessa1978@gmail.com)

**Yamile Leon**

Academy of Oncology Nurse &  
Patient Navigators  
[yamile.leon@amplify.com](mailto:yamile.leon@amplify.com)

**Brandon Leonard**

LUNGevity Foundation  
[bleonard@lungevity.org](mailto:bleonard@lungevity.org)

**Samson Lewis**

Takeda Pharmaceuticals  
[samson.lewis@takeda.com](mailto:samson.lewis@takeda.com)

**Ashley Lile**

Association of Community Cancer  
Centers  
[alile@acc-cancer.org](mailto:alile@acc-cancer.org)

**Karl Lobo**

Johnson & Johnson  
[Klobo1@its.jnj.com](mailto:Klobo1@its.jnj.com)

**Brittany Lovely**

American Cancer Society  
[brittany.lovely@cancer.org](mailto:brittany.lovely@cancer.org)

**Bryan Loy**

Humana  
[bloy@humana.com](mailto:bloy@humana.com)

**Aurora Lucas**

[auroralucas10@gmail.com](mailto:auroralucas10@gmail.com)

**Michael Mabry**

RadNet  
[michael.mabry@radnet.com](mailto:michael.mabry@radnet.com)

**Laura Makaroff**

American Cancer Society  
[Laura.Makaroff@cancer.org](mailto:Laura.Makaroff@cancer.org)

**Adoma Manful**

Vanderbilt University  
[adoma.a.manful@vanderbilt.edu](mailto:adoma.a.manful@vanderbilt.edu)

**Eugene Manley, Jr., PHD**

SCHEQ Foundation  
[emanley@scheq.org](mailto:emanley@scheq.org)

**Kate Mastalski**

American Cancer Society  
[kate.mastalski@cancer.org](mailto:kate.mastalski@cancer.org)

**John Matthews**

Ride Hard Breathe Easy  
[john@rhbe.org](mailto:john@rhbe.org)

**Dawn Mattoon**

Mercy BioAnalytics  
[dawn@mercybio.com](mailto:dawn@mercybio.com)

**Peter Mazzone**

Cleveland Clinic  
[mazzonp@ccf.org](mailto:mazzonp@ccf.org)

**Anita McGlothlin**

GO2 for Lung Cancer  
[amcglotlin@go2.org](mailto:amcglotlin@go2.org)

**Katie McMahon**

ACS Cancer Action Network  
[catherine.mcmahon@cancer.org](mailto:catherine.mcmahon@cancer.org)

**Lisa Mei**

Michigan Department of Health and Human Services  
[MeiL1@michigan.gov](mailto:MeiL1@michigan.gov)

**Maria Mejia**

Baylor College of Medicine  
[maria.mejia@bcm.edu](mailto:maria.mejia@bcm.edu)

**Whitney Mendel**

Roswell Park Comprehensive Cancer Center  
[whitney.mendel@roswellpark.org](mailto:whitney.mendel@roswellpark.org)

**Timothy Merchant**

RadNet  
[Timothy.merchant@radnet.com](mailto:Timothy.merchant@radnet.com)

**Claudia Miller**

Medical University of South Carolina  
[millercl@musc.edu](mailto:millercl@musc.edu)

**Eric Miller**

National Cancer Institute  
[eric.miller2@nih.gov](mailto:eric.miller2@nih.gov)

**Stacie Miller**

Moncrief Cancer Institute - UT Southwestern  
[stacie.miller@moncrief.com](mailto:stacie.miller@moncrief.com)

**Khadijah Mitchell**

Fox Chase Cancer Center  
[Khadijah.Mitchell@fcc.edu](mailto:Khadijah.Mitchell@fcc.edu)

**Drew Moghanaki**

UCLA Department of Radiation Oncology  
[drew.moghanaki@gmail.com](mailto:drew.moghanaki@gmail.com)

**Michelle Mollica**

National Cancer Institute  
[michelle.mollica@nih.gov](mailto:michelle.mollica@nih.gov)

**Dana Mueller**

Genentech  
[Mueller.dana@gene.com](mailto:Mueller.dana@gene.com)

**Phillip Munson**

Novocure  
[pmunson@novocure.com](mailto:pmunson@novocure.com)

**Kerry Murphy-O'Donnell**

American Cancer Society  
[kerry.murphyodonnell@cancer.org](mailto:kerry.murphyodonnell@cancer.org)

**Jenn Nagy**

American Cancer Society  
[jennifer.nagy@cancer.org](mailto:jennifer.nagy@cancer.org)

**Caitlin Nichols**

Wojcicki Foundation  
[caitlin@redwoodpacificllc.com](mailto:caitlin@redwoodpacificllc.com)

**Jeroen Nijwening**

RadNet  
[jeroen.nijwening@aidence.com](mailto:jeroen.nijwening@aidence.com)

**Maggie Nolan**

American College of Preventive Medicine  
[margaret.b.nolan@healthpartners.com](mailto:margaret.b.nolan@healthpartners.com)

**Eduardo Núñez**

UMass  
[eduardo.nunez2@baystatehealth.org](mailto:eduardo.nunez2@baystatehealth.org)

**Mindi Odom**

American Cancer Society  
[mindi.odom@cancer.org](mailto:mindi.odom@cancer.org)

**Jessica Olson**

Medical College of Wisconsin  
[jeolson@mcw.edu](mailto:jeolson@mcw.edu)

**Chidinma Onyia**

AstraZeneca  
[Chidinma.onyia@astrazeneca.com](mailto:Chidinma.onyia@astrazeneca.com)

**Raymond Osarogiagbon**

Baptist Memorial Healthcare  
[raymond.osarogiagbon@bmg.md](mailto:raymond.osarogiagbon@bmg.md)

**Jenny Ostien**

WVU Cancer Institute  
[jostien@hsc.wvu.edu](mailto:jostien@hsc.wvu.edu)

**Jamie Ostroff**

Memorial Sloan Kettering  
[ostroffj@mskcc.org](mailto:ostroffj@mskcc.org)

**Michelle Ottersbach**

[michelle.ottersbach@gmail.com](mailto:michelle.ottersbach@gmail.com)

**James Pantelas**

Department of Veterans Affairs  
[jpantelas@artemishrc.com](mailto:jpantelas@artemishrc.com)

**Shreya Papneja**

ALSCI  
[spapneja@mgh.harvard.edu](mailto:spapneja@mgh.harvard.edu)

**Elyse Park**

Mass General Hospital  
[epark@mgh.harvard.edu](mailto:epark@mgh.harvard.edu)

**Mary Pasquinelli**

University Of Illinois Chicago  
[mpasqu3@uic.edu](mailto:mpasqu3@uic.edu)

**Manali Patel**

Stanford University  
[manalip@stanford.edu](mailto:manalip@stanford.edu)

**Christopher Pena**

American Cancer Society  
[christopher.pena@cancer.org](mailto:christopher.pena@cancer.org)

**Laura Petrillo**

Massachusetts General Hospital  
[lpetrillo2@mgh.harvard.edu](mailto:lpetrillo2@mgh.harvard.edu)

**Paul Pinsky**

NCI  
[pp4f@nih.gov](mailto:pp4f@nih.gov)

**Alexandra Potter**

ALCSI  
[apotter8@mg.harvard.edu](mailto:apotter8@mg.harvard.edu)

**Elridge Proctor**

GO2 for Lung Cancer  
[Eproctor@go2.org](mailto:Eproctor@go2.org)

**Namita Puran**

MedStar Washington Hospital  
 Center  
[namita.puran@medstar.net](mailto:namita.puran@medstar.net)

**Elissa Quinn**

AstraZeneca  
[elissa.quinn@astrazeneca.com](mailto:elissa.quinn@astrazeneca.com)

**Shweta Raman**

GWU ALSCI  
[sraman03@gmail.com](mailto:sraman03@gmail.com)

**Sanjana Rana**

Office of Senator Ed Markey (D-MA)  
[sanjana\\_rana@markey.senate.gov](mailto:sanjana_rana@markey.senate.gov)

**Nataly Reed**

Parkland Health  
[nataly.reed@phhs.org](mailto:nataly.reed@phhs.org)

**Matthew Reiss**

GO2 for Lung Cancer  
[mreiss@go2.org](mailto:mreiss@go2.org)

**Daniel Reuland**

UNC Chapel Hill  
[dreuland@med.unc.edu](mailto:dreuland@med.unc.edu)

**Nancy Rigotti**

Harvard Medical School  
[nrigotti@partners.org](mailto:nrigotti@partners.org)

**M. Patricia Rivera**

University of Rochester  
[patricia\\_rivera@urmc.rochester.edu](mailto:patricia_rivera@urmc.rochester.edu)

**Senkuta Riverson**

DC Health  
[senkuta.riverson@dc.gov](mailto:senkuta.riverson@dc.gov)

**Trish Rizk**

[prizk@mfa.gwu.edu](mailto:prizk@mfa.gwu.edu)

**Albert Rizzo**

American Lung Association  
[albert.rizzo@lung.org](mailto:albert.rizzo@lung.org)

**Theresa Roelke**

MaineHealth  
[Theresa@Roelke.org](mailto:Theresa@Roelke.org)

**Elizabeth Rohan**

Centers for Disease Control and  
 Prevention  
[erohan@cdc.gov](mailto:erohan@cdc.gov)

**Lauren Rosenthal**

ACS NLCRT  
[lauren.rosenthal@cancer.org](mailto:lauren.rosenthal@cancer.org)

**Humay Sadig**

ALSCI  
[hsadig369@gwu.edu](mailto:hsadig369@gwu.edu)

**Liora Sahar**

American Cancer Society  
[liora.sahar@cancer.org](mailto:liora.sahar@cancer.org)

**Lori Sakoda**

Kaiser Permanente Northern  
 California  
[lori.sakoda@kp.org](mailto:lori.sakoda@kp.org)

**Leigh Sampson**

American Cancer Society  
[LEIGH.SAMPSON@CANCER.ORG](mailto:LEIGH.SAMPSON@CANCER.ORG)

**Anu Sangraula**

[as5229@georgetown.edu](mailto:as5229@georgetown.edu)

**Kristen Santiago**

LUNGeVity Foundation  
[ksantiago@lungevity.org](mailto:ksantiago@lungevity.org)

**Matthew Schabath**

H. Lee Moffitt Cancer Center &  
 Research Institute  
[matthew.schabath@moffitt.org](mailto:matthew.schabath@moffitt.org)

**Elizabeth Scharnetzki**

MaineHealth Institute for Research  
[elizabeth.scharnetzki@mainehealth.org](mailto:elizabeth.scharnetzki@mainehealth.org)

**Shelley Schenning**

RadNet  
[shelley.schenning@radnet.com](mailto:shelley.schenning@radnet.com)

**Amy Schwartz**

Penn Medicine, PPMC  
[amy.schwartz@penmedicine.upenn.edu](mailto:amy.schwartz@penmedicine.upenn.edu)

**Samuel Schwartz**

GW Lung Cancer Society  
[samuel.schwartz@gwmail.gwu.edu](mailto:samuel.schwartz@gwmail.gwu.edu)

**Andrew Scott**

Bristol Myers Squibb  
[andrew.scott@bms.com](mailto:andrew.scott@bms.com)

**NFN Scout**

National LGBT Cancer Network  
[scout@cancer-network.org](mailto:scout@cancer-network.org)

**Debbie Semmel**

Duke University Health System  
[deborah.semmel@duke.edu](mailto:deborah.semmel@duke.edu)

**Priyanka Senthil**

ALSCI  
[psenthil@mg.harvard.edu](mailto:psenthil@mg.harvard.edu)

**Lecia Sequist**

Mass General Brigham  
[lvsequist@mgb.org](mailto:lvsequist@mgb.org)

**Sarah Shafir**

American Cancer Society  
[sarah.shafir@cancer.org](mailto:sarah.shafir@cancer.org)

**Rhea Sharma**

[rhea.sharma@gwmail.gwu.edu](mailto:rhea.sharma@gwmail.gwu.edu)

**Aharona Shuali**

Nucleix  
[aharona@nucleix.com](mailto:aharona@nucleix.com)

**Gerard Silvestri**

Medical University of South  
 Carolina  
[silvestri@muscc.edu](mailto:silvestri@muscc.edu)

**Keith Singer**

Catch It In Time  
[Ksinger@catchitintime.org](mailto:Ksinger@catchitintime.org)

**Anurag Singh**

Roswell Park Comprehensive  
Cancer Center  
[Anurag.Singh@RoswellPark.org](mailto:Anurag.Singh@RoswellPark.org)

**Christopher Slatore**

VA National Center for Lung Cancer  
Screening  
[christopher.slatore@va.gov](mailto:christopher.slatore@va.gov)

**Michael Smith**

Mercy BioAnalytics  
[michael@mercybio.com](mailto:michael@mercybio.com)

**Robert Smith**

American Cancer Society  
[robert.smith@cancer.org](mailto:robert.smith@cancer.org)

**Deepti Srinivasan**

[deepti.srinivasan@tufts.edu](mailto:deepti.srinivasan@tufts.edu)

**Anne Stangl**

CDC  
[atd9@cdc.gov](mailto:atd9@cdc.gov)

**Jody Steinhardt**

NYC Health + Hospitals  
[steinhaj1@nychhc.org](mailto:steinhaj1@nychhc.org)

**John Studdard**

CHEST  
[Jestuddard@gmail.com](mailto:Jestuddard@gmail.com)

**Jamie Studts**

University of Colorado Cancer  
Center  
[jamie.studts@cuanschutz.edu](mailto:jamie.studts@cuanschutz.edu)

**Sabah Sumo**

DC Health  
[sabah.sumo@dc.gov](mailto:sabah.sumo@dc.gov)

**Virginia Sun**

City of Hope  
[vsun@coh.org](mailto:vsun@coh.org)

**Nichole Tanner**

Medical University of South  
Carolina  
[nichole.tanner@va.gov](mailto:nichole.tanner@va.gov)

**Kathryn Taylor**

Georgetown Lombardi  
Comprehensive Cancer Center  
[taylorkl@georgetown.edu](mailto:taylorkl@georgetown.edu)

**Carey Thomson**

Mount Auburn Hospital/BI Lahey  
Health, Harvard Medical School  
[cthompson@mah.harvard.edu](mailto:cthompson@mah.harvard.edu)

**Robbie Tilley**

American Cancer Society  
[ROBBIE.TILLEY@CANCER.ORG](mailto:ROBBIE.TILLEY@CANCER.ORG)

**Brian Tomlinson**

Foundation Medicine  
[btomlinson@foundationmedicine.com](mailto:btomlinson@foundationmedicine.com)

**Haley Tupper**

[htupper@mednet.ucla.edu](mailto:htupper@mednet.ucla.edu)

**Brenna VanFrank**

CDC  
[ydj5@cdc.gov](mailto:ydj5@cdc.gov)

**Tom Varghese, Jr.**

University of Utah  
[thomas.varghese@hsc.utah.edu](mailto:thomas.varghese@hsc.utah.edu)

**Jeffrey Velotta**

Kaiser Permanente Northern  
California  
[jeffrey.b.velotta@kp.org](mailto:jeffrey.b.velotta@kp.org)

**Michael Vicari**

Nucleix  
[mvicari@nucleix.com](mailto:mvicari@nucleix.com)

**Aubrey Villalobos**

National Cancer Institute  
[aubrey.villalobos@nih.gov](mailto:aubrey.villalobos@nih.gov)

**Michelle Vislosky**

Philips Healthcare  
[michelle.vislosky@philips.com](mailto:michelle.vislosky@philips.com)

**Robert Volk**

The University of Texas MD  
Anderson Cancer Center  
[BVolk@mdanderson.org](mailto:BVolk@mdanderson.org)

**Ashley Walton**

American College of Radiology  
[awalton@acr.org](mailto:awalton@acr.org)

**Daniel West**

[Dpwest1992@gmail.com](mailto:Dpwest1992@gmail.com)

**J. Lee Westmaas**

American Cancer Society  
[LEE.WESTMAAS@CANCER.ORG](mailto:LEE.WESTMAAS@CANCER.ORG)

**Julia Whealan**

Georgetown Lombardi  
Comprehensive Cancer Center –  
Cancer Prevention and Control  
Program  
[jw2057@georgetown.edu](mailto:jw2057@georgetown.edu)

**Renda Wiener**

VA Boston Healthcare System  
[renda.wiener@va.gov](mailto:renda.wiener@va.gov)

**Sarah Wienke**

American Cancer Society  
[sarah.wienke@cancer.org](mailto:sarah.wienke@cancer.org)

**Randi Williams**

Georgetown University  
[rmw27@georgetown.edu](mailto:rmw27@georgetown.edu)

**Kelly Willingham**

Oklahoma Hospital Association  
[kwillingham@okoha.com](mailto:kwillingham@okoha.com)

**Ignacio Wistuba**

The University of Texas MD  
Anderson Cancer Center  
[iwistuba@mdanderson.org](mailto:iwistuba@mdanderson.org)

**Evan Wolff**

Novocure  
[ewolff@novocure.com](mailto:ewolff@novocure.com)

**Douglas Wood**

University of Washington  
[dewood@u.washington.edu](mailto:dewood@u.washington.edu)

**Chuanbo Xu**

Freenome, Inc.  
[chuanbo.xu@freenome.com](mailto:chuanbo.xu@freenome.com)

**Chi-Fu Jeffrey Yang, MD**

MGH Thoracic Surgery  
[cjyang@mgh.harvard.edu](mailto:cjyang@mgh.harvard.edu)

**David Yankelevitz**

Icahn School of Medicine  
[david.yankelevitz@mountsinai.org](mailto:david.yankelevitz@mountsinai.org)

**Sarah Zamarripa**

[sarah.zamarripa@moncrief.com](mailto:sarah.zamarripa@moncrief.com)

**Andrew Zebrak**

Intuitive Surgical  
[andrew.zebrak@intusurg.com](mailto:andrew.zebrak@intusurg.com)

**Cathy Zoller**

American Cancer Society  
[cathleen.zoller@cancer.org](mailto:cathleen.zoller@cancer.org)



# ACS NLCRT Organizational Members

A Breath of Hope Lung Foundation  
AbbVie  
Academy of Oncology Nurse & Patient Navigators  
Advocate Aurora Lutheran General Hospital  
Aetna  
Alaska Cancer Partnership  
ALK Fusion  
ALK Positive  
American Academy of Family Physicians  
American Association for Thoracic Surgery  
American Association for Women in Radiology  
American Association of Nurse Practitioners  
American Association of Physicists in Medicine  
American Cancer Society  
American Cancer Society Cancer Action Network  
American College of Chest Physicians (CHEST)  
American College of Preventive Medicine  
American College of Radiology  
American College of Surgeons Commission on Cancer  
American Indian Cancer Foundation  
American Lung Association  
American Lung Cancer Screening Initiative  
American Medical Women's Association  
American Public Health Association  
American Society for Radiation Oncology  
American Society of Clinical Oncology  
American Society of Preventive Oncology  
American Telehealth Association  
American Thoracic Society  
Amgen  
Anne Arundel Medical Center  
Ascension Sacred Heart Cancer Center (FL)  
Association for the Treatment of Tobacco Use and Dependence  
Association of Community Cancer Centers  
Association of State & Territorial Health Officials  
AstraZeneca  
AvMed  
Baptist Cancer Center  
Barbara Ann Karmanos Cancer Institute  
Beaumont Health System  
bioAffinity Technologies, Inc.  
Biodesix, Inc.  
Boehringer Ingelheim  
Breath of Hope Kentucky  
Breathe Biomedical, Inc.  
Bristol Myers Squibb  
Bristol Myers Squibb Foundation  
Bronson Oncology  
Cancer Support Community  
CancerCare  
Caring Ambassadors  
Catch It In Time  
CDC Division of Cancer Prevention and Control  
CDC Office on Smoking and Health  
Center for Health Law & Policy Innovation of Harvard Law School  
Centers for Medicare and Medicaid Services  
Chris Draft Family Foundation  
ChristianaCare Health System  
Citizens for Radioactive Radon Reduction  
Cleveland Clinic  
Commoner Center, City University of New York  
Daiichi-Sankyo  
Dana-Farber Cancer Institute  
DC Health  
Delfi Diagnostics, Inc.  
Dusty Joy Foundation (LiveLung)  
EGFR Resisters  
Elevance  
Eli Lilly and Company  
EMD Serono, Inc.  
Essentia Health Cancer Center (ND)  
Exact Sciences  
Fleischner Society  
Foundation Medicine  
Fred Hutchinson Cancer Center  
Fred Hutchinson Cancer Center Office of Community Outreach & Engagement  
Free ME From Lung Cancer  
Genentech

Georgetown University Lombardi Cancer Center  
 George Washington University  
 Georgia Lung Cancer Roundtable  
 Gilead Sciences  
 GO2 Foundation for Lung Cancer  
 GRAIL  
 Grandview Cancer Center  
 Guardant Health  
 Health First Cancer Institute (Florida)  
 Hillsdale Hospital (Michigan)  
 Houston Methodist  
 Humana  
 Huntsman Cancer Institute at the University of Utah  
 Illinois Lung Cancer Roundtable  
 Incyte  
 Indian Health Service  
 Inspira Health  
 Intercultural Cancer Council  
 International Association for the Study of Lung  
 Cancer  
 International Cancer Action Network  
 International Early Lung Cancer Action Program  
 Intuitive  
 Janssen Pharmaceuticals  
 Jefferson Health  
 Johnson & Johnson Lung Cancer Initiative  
 Kaiser Permanente Northern California  
 Kentucky Cancer Consortium  
 Kentucky LEADS Collaborative  
 KRas Kickers  
 Lee Health Regional Cancer Center  
 Lehigh Valley Health Network  
 LGBT HealthLink  
 Life and Breath  
 LuCa National Training Network  
 Lung Cancer Awareness Month (LCAM) Coalition  
 Lung Cancer Foundation of America  
 Lung Cancer Initiative of North Carolina  
 Lung Cancer Research Foundation  
 Lung Health Services, Inc.  
 LungCAN  
 LUNGeivity Foundation  
 Lung Screening Network  
 Mahaska Health  
 Maimonides Medical Center  
 Maine Lung Cancer Coalition  
 Maryland DC Society of Clinical Oncology  
 Maryland Department of Health  
 Median Technologies  
 Medical Imaging & Technology Alliance  
 Medical University of South Carolina  
 MedMyne  
 Medtronic  
 Memorial Sloan Kettering Cancer Center  
 Merck  
 MeVis Medical Solutions  
 Michigan Department of Health and Human  
 Services  
 Mississippi Lung Cancer Roundtable  
 Missouri Lung Cancer Coalition  
 Moffitt Cancer Center  
 Mount Sinai Health System  
 National Alliance for Hispanic Health  
 National Association of Chronic Disease Directors  
 National Cancer Institute  
 National Committee for Quality Assurance  
 National Comprehensive Cancer Network  
 National Minority Quality Forum  
 New York City Health & Hospital  
 New York State Lung Cancer Screening Action Team  
 North American Association of Central Cancer  
 Registries  
 North American Quitline Consortium  
 North Florida Regional Medical Center  
 Northwest Community Hospital  
 Northwestern Memorial HealthCare  
 Northwestern Memorial Hospital  
 Novartis  
 Novocure  
 Nucleix  
 NYU Langone Health Perlmutter Cancer Center  
 Oatmeal Health  
 Oklahoma Hospital Association  
 Oklahoma State Department of Health  
 Oncimmune USA  
 Optellum Ltd  
 Patient Advocate Foundation  
 Patient Centered Primary Care Coalition  
 Penn Presbyterian Medical Center  
 Pennsylvania Department of Health  
 Pfizer, Inc.  
 Philips North America, LLC  
 Prevent Cancer Foundation  
 ProLung  
 Quality Insights  
 Radiology Health Equity Coalition  
 RadNet  
 Regeneron  
 Ride Hard Breathe Easy  
 Riverain Technologies, LLC  
 Roche  
 ROS1ders

Roswell Park Comprehensive Cancer Center  
Rutgers Cancer Institute of New Jersey  
Saint Joseph Mercy Health System  
Sanford Health  
Sanofi-Genzyme  
Sarasota Memorial Health Care System  
Seidman Cancer Center  
Silver Cross Hospital (IL)  
Siteman Cancer Center  
Society for Behavioral Medicine  
Society for Public Health Education  
Society for Research on Nicotine and Tobacco  
Society of General Internal Medicine  
Society of Interventional Radiology  
Society of Thoracic Radiology  
Society of Thoracic Surgeons  
Stanford Medicine  
Steward Medical Group  
Sustainable Healthy Communities, LLC  
Takeda Oncology  
Tampa General Hospital

Temple Health Thoracic Surgery  
Thermo Fischer Scientific  
Thynk Health  
UCLA Department of Surgery  
UCSF Helen Diller Family Comprehensive Cancer Center  
UCSF Smoking Cessation Leadership Center  
University of Kansas Cancer Center  
University of Maryland School of Medicine  
University of Michigan Rogel Cancer Center  
University of Mississippi Cancer Center and Research Institute  
University of Texas Southwestern Moncrief Cancer Institute  
University of Virginia Cancer Center  
University of Washington  
University of Wisconsin Carbone Comprehensive Cancer Center  
Upstage Lung Cancer  
Vanderbilt-Ingram Cancer Center  
VA-PALS (Partnership to Increase Access to Lung Screening)  
Veterans Health Administration  
VisionGate  
Wake Forest Comprehensive Cancer Center  
XACT Robotics  
Yale Cancer Center

Save the Date!

December 9-10, 2024



# Thank you ACS NLCRT Sponsors!



NATIONAL  
LUNG CANCER  
ROUNDTABLE



GILEAD  
Creating Possible



Bristol Myers Squibb™



MERCK

sanofi

REGENERON  
SCIENCE TO MEDICINE®



ONCOLOGY



Daiichi-Sankyo

AMGEN



NOVARTIS

ACR®  
AMERICAN COLLEGE OF  
RADIOLOGY

Additional thanks to AbbVie, Boehringer Ingelheim, Foundation Medicine,  
Guardant Health, Novocure, and Roche